Victoza reduces CV risk in type 2 diabetes regardless of severe hypoglycemia events

Findings from a post-hoc analysis of the LEADER cardiovascular (CV) outcomes trial showed that the Novo Nordisk (NOV: N) treatment Victoza (liraglutide) resulted in similar reductions in the chance of major CV events in people with type 2 diabetes at high CV risk, regardless of whether they experienced an episode of severe hypoglycemia during the study.

The results were presented by the Danish pharma company late on Monday at the American Diabetes Association 77th Scientific Sessions.

For the overall LEADER population, regardless of treatment group, people who experienced a severe hypoglycemic episode were at a significantly greater risk of major cardiovascular adverse events (CV death, non-fatal heart attack or non-fatal stroke), CV-death or non-CV death.